Johnson & Johnson

News

China clears ViiV, J&J injectable HIV treatment

ViiV Healthcare and Johnson & Johnson have been granted approval in China for a long-acting HIV therapy that frees patients from the need to take daily pills to keep t

News

ESMO: J&J’s Tagrisso challenge, and other highlights

With Europe’s premier cancer congress ESMO now finished, we close our coverage with a look at some other important new studies that generated a buzz at the show.

News

AZ’s Tagrisso plus chemo get fast FDA review for lung cancer

AstraZeneca will hear back from the FDA in the first quarter of next year about its recent filing of Tagrisso in combination with chemotherapy as a first-line treatment fo

News

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used S

News

J&J doublet beats Tagrisso in first-line lung cancer

AstraZeneca’s Tagrisso could face some serious competition as a first-line targeted therapy for advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC), in

News

Anthos hails win over Xarelto with novel anticoagulant

Anthos Therapeutics says a phase 2b trial of its factor XI inhibitor anticoagulant abelacimab has been stopped early due to an “overwhelming” reduction in bleeding complic

China clears ViiV, J&J injectable HIV treatment

ESMO: J&J’s Tagrisso challenge, and other highlights

AZ’s Tagrisso plus chemo get fast FDA review for lung cancer

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

J&J doublet beats Tagrisso in first-line lung cancer

Anthos hails win over Xarelto with novel anticoagulant

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Johnson & Johnson

Editor's Picks